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Abstract
Background: Early natural menopause, the cessation of ovarian function before age 45 y, is positively associated
with cardiovascular disease and other conditions. Dietary vitamin D intake has been inversely associated with early
menopause; however, no previous studies have evaluated risk with regard to plasma 25-hydroxyvitamin D [25(OH)D]
concentrations.
Objective: We prospectively evaluated associations of total and free 25(OH)D and vitamin D–binding protein (VDBP)
concentrations and the risk of early menopause in a case-control study nested within the Nurses’ Health Study II (NHS2).
We also considered associations of 25(OH)D and VDBP with anti-Müllerian hormone (AMH) concentrations.
Methods: The NHS2 is a prospective study in 116,430 nurses, aged 25–42 y at baseline (1989). Premenopausal plasma
blood samples were collected between 1996 and 1999, from which total 25(OH)D and VDBP concentrations were
measured and free 25(OH)D concentrations were calculated. Cases experienced menopause between blood collection
and age 45 y (n = 328) and were matched 1:1 by age and other factors to controls who experienced menopause after
age 48 y (n = 328). Conditional logistic regression models were used to estimate ORs and 95% CIs for early menopause
according to each biomarker. Generalized linear models were used to estimate AMH geometric means according to each
biomarker.
Results: After adjusting for smoking and other factors, total and free 25(OH)D were not associated with early
menopause. Quartile 4 compared with quartile 1 ORs were 1.04 (95% CI: 0.60, 1.81) for total 25(OH)D and 0.70 (95%
CI: 0.41, 1.20) for free 25(OH)D. 25(OH)D was unrelated to AMH concentrations. VDBP was positively associated with
early menopause; the OR comparing the highest with the lowest quartile of VDBP was 1.80 (95% CI: 1.09, 2.98).
Conclusions:Our findings suggest that total and free 25(OH)D are not importantly related to the risk of earlymenopause.
VDBP may be associated with increased risk, but replication is warranted. J Nutr 2018;148:1445–1452.
Keywords: vitamin D, 25-hydroxyvitamin D, vitamin D–binding protein, early menopause, ovarian aging,
anti-Müllerian hormone
Introduction
Early menopause, which is the cessation of ovarian function
before the age of 45 y, affects 10% of women in Western
populations (1). Women who experience early menopause
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are at increased risk of premature mortality and cognitive
decline, osteoporosis, and cardiovascular disease, as well as
other adverse health outcomes (2–5). Early menopause may
also be problematic for couples trying to conceive, because
female fertility declines drastically during the 10 y leading up
to menopause (6). Couples unable to conceive as they wish
may experience substantial financial and psychological conse-
quences, particularly as women increasingly delay childbearing
into the later reproductive years (1, 7). As such, it is important to
identify modifiable lifestyle factors that may be related to early
menopause risk, including diet.
Accelerated ovarian aging, the mechanism thought to
underlie early menopause, is characterized by a decline in the
quantity and quality of the ovarian follicle pool (7). During
the reproductive years, primordial follicle growth and transition
© 2018 American Society for Nutrition. All rights reserved.
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to primary follicles are inhibited by anti-Müllerian hormone
(AMH), a glycoprotein secreted by the granulosa cells of
primary, secondary, and small antral follicles.Notably, a vitamin
D response element has been identified in the promoter region
of the AMH gene (8), suggesting a potential role of vitamin
D in AMH secretion and thus follicle recruitment. In line with
this hypothesis, laboratory studies have shown that vitamin D
upregulates AMH mRNA expression in both human prostate
cells and granulosa cells of hens (9, 10).
Findings of a recent study in the Nurses’ Health Study
(NHS) II (NHS2) cohort suggest that vitamin D intake
from food sources, particularly dairy sources, is associated
with a lower risk of early menopause (11). Because vitamin
D is obtained through dietary intake as well as sunlight
exposure, concentrations of 25-hydroxyvitamin D [25(OH)D],
the primary circulating metabolite of vitamin D, is a better
indicator of vitamin D status than dietary intake alone. To
our knowledge, no previous studies have evaluated 25(OH)D
concentrations and the risk of early menopause and findings
of epidemiologic studies evaluating 25(OH)D concentrations
and AMH are conflicting (12–15). One study found that
AMH concentrations exhibit seasonal variation correlated with
25(OH)D concentrations and that vitamin D supplementation
prevented a seasonal decline in AMH concentrations (13). An
additional study in US women found 25(OH)D to be positively
associated with AMH concentrations (12), whereas 3 more-
recent studies reported no association (14, 15).
It is also currently unclear whether measures of total com-
pared with free 25(OH)D concentrations may have different
relations with ovarian aging. At any given time, >99% of
vitamin D in the body is bound to vitamin D–binding protein
(VDBP) or albumin, leaving <1% unbound (16). Because
VDBP concentrations influence the bioavailability of vitamin
D, assessing total compared with free 25(OH)D concentrations
as well as concentrations of VDBP may be important for
understanding the potential relation of vitamin D and early
menopause. In fact, recent epidemiologic studies have observed
that the free 25(OH)D fraction, as compared with total
25(OH)D, is more strongly associated with several health
outcomes such as bone mineral density (17) and colorectal
cancer (18).
In light of the lack of studies evaluating vitamin D status and
early menopause, the aims of the present nested case-control
study were thus to evaluate associations of total 25(OH)D,
free 25(OH)D, and VDBP concentrations and the risk of early
menopause among participants of the NHS2.
Methods
The NHS2 is a prospective study in 116,429 female US registered nurses
who were 25–42 y old in 1989 when they responded to a mailed
baseline questionnaire. Information with regard to lifestyle behaviors
and medical conditions are collected through biennial questionnaires,
for which the follow-up rate for each cycle has been ≥89%. The study
protocol was approved by the institutional review board at Brigham
and Women’s Hospital in Boston, Massachusetts.
Case and control ascertainment. On the 1989 baseline ques-
tionnaire, nurses were asked if their menstrual periods had ceased
permanently (i.e., no periods for ≥12 mo) and were provided the
following response options: 1) no (premenopausal),2) yes (nomenstrual
periods), 3) yes (had menopause but now have periods induced by
hormones), and 4) not sure (e.g., started hormones before cessation of
periods). Nurses who indicated that their periods had ceased were then
asked the following questions: 1) At what age did your periods cease
(open response) and 2) for what reason did your periods cease (response
options were surgery, radiation or chemotherapy, and natural)? Women
were also asked about their current and past use of menopausal
hormone therapy (HT). Questions with regard to menopausal status
and use of HT were then repeated on all subsequent questionnaires.
A small number of women reported being postmenopausal on
one questionnaire after a long interval of amenorrhea (>12 mo),
only to have periods return again and report being premenopausal
on a subsequent questionnaire. For these women, we defined age
at menopause as the age after which periods were absent for
≥12mo, and then confirmed that this status persisted for≥3 consecutive
questionnaires in order to reduce potential for misclassification of early
menopause.
Blood sample collection. Participants of the NHS2 who had not
previously been diagnosed with cancer (n = 92,888) were invited
to provide blood samples between 1996 and 1999. During this time
period, participants were aged 32–54 y. Premenopausal women who
were not pregnant and were not using oral contraceptives (OCs) or
menopausal HT were asked to provide 2 samples during the span of
one menstrual cycle. The first sample was to be collected during the
follicular phase (days 3–5 of the menstrual cycle) and the second was to
be collected during the luteal phase (7–9 d before the start of the next
menses). Women who were using OCs or menopausal HT were asked
to provide a single untimed sample, and women who reported irregular
menstrual cycles were asked to collect a luteal phase sample 22 d after
the last menses. To confirm timing and menstrual cycle phase of the
samples, women completed a postcard at the start of their next menses.
Upon receipt, blood samples were centrifuged, separated into plasma,
buffy, and RBC components, and then stored at ≤ –130°C in nitrogen
freezers.
Among eligible women, 29,611 provided a sample and ∼23,000 of
these women were premenopausal at the time of blood draw. Women
who provided samples were similar to the entire NHS2 cohort, having
equivalent BMI (in kg/m2; 26 and 26) and parity (1.9 and 1.9 children)
and comparable proportions of ever smoking (34% compared with
36%) and history of OC use (86% compared with 88%), as well as
other factors (19).
Because we were interested in prospectively evaluating the relation
of plasma 25(OH)D concentrations and risk of early menopause,
we limited eligibility to women who experienced menopause after
blood draw. In addition, our study sample was limited to women
without a previous diagnosis of cancer (other than nonmelanoma skin
cancer), myocardial infarction, stroke, coronary artery bypass surgery,
or percutaneous coronary intervention and women who had available
plasma samples. Cases of early menopause were then defined as women
reporting natural menopause (i.e., not due to surgery or chemotherapy)
before the age of 45 y during follow-up. To reduce the potential
for misclassification of early menopause status, eligible controls were
women who experienced menopause after age 48 y (quartile 3 of the
IQR). Eligible cases (n = 328) were then matched 1:1 to controls
according to age at blood collection (within 4 mo), time of day of blood
collection, month of collection (within 3 mo), sample type (luteal phase
or untimed), and fasting status (Figure 1).
Laboratory assays. Plasma 25(OH)D, VDBP, albumin, and AMH
were measured in the laboratory of Nader Rifai at Boston’s Children’s
Hospital. Immunoassays were used for the measurement of plasma
25(OH)D (Immunodiagnostic Systems, Inc.) and plasma VDBP (R&D
Systems). The immunoassay used to measure plasma VDBP was a
monoclonal antibody. Plasma AMH was measured by using the pico
AMH assay from ANSH Labs.
With the use of measured values of plasma total 25(OH)D, VDBP,
and albumin for each individual, we calculated each participant’s
plasma free 25(OH)D concentration according to the following
1446 Purdue-Smithe et al.
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116,429 NHS2 participants (1989)
29,611 provided blood 
sample in 1996-1999
~15,000 premenopausal and 
age <45 y at blood draw
328 cases with 
natural menopause 
at age <45 y
328 controls with 
menopause at age ≥48 y, 
matched 1:1 with cases
Exclusions: cancer other than 
nonmelanoma skin cancer, 
death, loss-to-follow-up; 
declined participation in blood 
collection 
Exclusions: confirmed cancer other than non-
melanoma skin cancer prior to blood draw; 
confirmed cardiovascular disease prior to blood 
draw; unavailable plasma; death; loss-to-
follow-up; hysterectomy or oophorectomy 
before menopause; radiation or chemotherapy-
induced menopause
Exclusions: confirmed cancer other than non-
melanoma skin cancer prior to blood draw; 
confirmed cardiovascular disease prior to blood 
draw; unavailable plasma; death; loss-to-follow-
up; hysterectomy or oophorectomy before age 
48 y; radiation or chemotherapy-induced 
menopause before age 48 y
FIGURE 1 Participant flowchart. NHS2, Nurses’ Health Study II.
equation (20):
Free 25(OH)D
(
pmol/L
)
= total 25(OH)D (nmol/L)
1 +
[
6 × 103 × albumin (g/L)
]
+
[
7 × 108 ×VDBP (μmol/L)
]
(1)
To prevent potential exposure measurement error related to case
status, laboratory personnel were blinded to case/control status for all
assays. Samples were labeled by number; and matched case-control sets
were handled together, shipped in the same batch, and assayed in the
same analytical run. Masked quality-control samples were randomly
interspersed among case-control samples and were analyzed in each
batch. The CVs for biomarkers were 4.9% for total 25(OH)D, 7.2%
for VDBP, and 8.6% for AMH.
Assessment of covariates. Variables used as matching factors,
including age at blood collection, time of day of blood collection,
month of collection, sample type (luteal phase or untimed), and fasting
status, were assessed at the time of blood draw. We also considered the
following variables for inclusion in multivariable models on the basis
of previous studies of risk factors for early menopause: race/ethnicity,
smoking, BMI, parity, physical activity, OC use and duration, duration
of breastfeeding, alcohol intake, and vegetable protein intake. Height
and race/ethnicity were assessed at baseline in 1989 and information
with regard to smoking status,weight (to calculate BMI), alcohol intake,
fasting status, and menstrual cycle phase were collected at the time of
blood draw by separate questionnaire.Updated informationwith regard
to smoking, weight, OC use, parity, and breastfeeding was assessed
on biennial questionnaires beginning in 1989. Physical activity was
assessed in 1989, 1991, 1997, 2001, and 2005 by using validated
questionnaires (21). Finally, validated FFQs administered every 4 y were
used to assess dietary intake of total calories, alcohol, and vegetable
protein (22–24). Intakes of nutrients were adjusted for total energy
using the residual method (25). For time-varying covariates,wemodeled
variables that corresponded to questionnaires closest in time to blood
collection for each individual. Women with missing covariate data were
assigned to a missing indicator.
Statistical analysis. We used chi-square and t tests to compare
characteristics of early menopause cases and controls at the time of
blood draw and histogram and normality plots to assess the normality
of biomarker data. Participants were divided into quartiles of total
25(OH)D, free 25(OH)D, and VDBP on the basis of the distribution of
these biomarkers in the control group. Likelihood ratio tests comparing
nested models were used to assess the global significance of each
biomarker. We also categorized participants according to the following
cutoffs: <50, 50 to <75, and ≥75 nmol/L (26). For analyses using
continuous biomarker data, we identified and removed outliers by
using the Rosner extreme studentized deviate test and standardized
continuous variables to aid in interpretability. Relations of total and
free 25(OH)D with log(AMH) were evaluated by using multivariable
generalized linear models. We then back-calculated AMH geometric
means and 95% CIs according to each quartile of total and free
25(OH)D.
For each exposure, we used conditional logistic regression to
calculate ORs and 95% CIs, adjusting for matching factors only.
We then controlled for potential confounders of the 25(OH)D–early
menopause relation using multivariable conditional logistic regression.
Because none of the covariates that were tested produced a change
in exposure estimates >10%, covariates in multivariable models were
selected if they were importantly associated with the outcome in our
population.
To assess potential nonlinear associations of each biomarker
exposure with the risk of early menopause, we additionally conducted
restricted cubic spline models. For these models, we specified 4 knots in
order to evaluate the individual spline term contributions to the model
fit and overall test for nonlinearity.
We additionally used restricted cubic spline models to assess
potential nonlinear associations of each biomarker with the risk of early
menopause. To assess potential variation in associations according to
age, we stratified our analyses by median age at blood draw (40 y).
Second, because vitamin D is sequestered in adipose tissue (27), we
assessed potential BMI effect modification by stratifying according to 2
categories of BMI (<25 and ≥25). Third, to evaluate potential seasonal
variation in the 25(OH)D–early menopause relation, we stratified our
analyses by season of blood collection (winter/spring and summer/fall).
We also conducted sensitivity analyses to determine the robustness
of estimates in primary analyses. Autoimmune conditions such as
multiple sclerosis, rheumatoid arthritis, and lupus may be associated
Vitamin D status and early menopause 1447
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TABLE 1 Characteristics of early menopause cases and
controls at blood draw (1996–1999): NHS21
Characteristic
Cases
(n = 328)
Controls
(n = 328) P 2
Age,3 y 40.2 ± 2.8 40.2 ± 2.8 0.99
BMI, kg/m2 25.4 ± 0.3 25.0 ± 0.3 0.10
Age at menarche, y 12.4 ± 0.1 12.3 ± 0.1 0.57
Physical activity, MET-h/wk 81.5 ± 14.7 72.5 ± 12.9 0.12
Parity, n 1.8 ± 0.1 1.9 ± 0.1 0.55
Duration of breastfeeding, mo 4.8 ± 0.2 5.0 ± 0.2 0.25
Alcohol intake, g/d 3.3 ± 0.3 3.9 ± 0.4 <0.01
Vegetable protein intake, % total kcal/d 5.2 ± 0.01 5.5 ± 0.01 0.09
Total vitamin D intake, IU/d 348 ± 13.3 381 ± 15.1 0.03
Supplemental vitamin D intake 125 ± 10.9 156 ± 11.7 0.19
Dietary vitamin D intake 218 ± 6.5 217 ± 6.4 0.81
Dairy vitamin D intake 122 ± 6.2 118 ± 5.7 0.15
Total calcium intake, mg/d 990 ± 24.5 1062 ± 27.6 0.03
Supplemental calcium intake 146 ± 15.7 186 ± 19.7 <0.001
Dietary calcium intake 841 ± 18.3 865 ± 17.1 0.29
Dairy calcium intake 537 ± 18.6 542 ± 17.3 0.27
Non-Hispanic white, % 95.3 98.8 0.01
Season of blood draw, % 0.64
Summer/fall 50.0 50.0
Winter/spring 51.8 48.2
Current smoker, % 14.0 9.2 0.05
Smoking duration,4 pack-years 12.9 ± 1.0 10.5 ± 0.7 0.02
Current OC user, % 1.8 3.7 0.15
OC use duration,5 mo 59.6 ± 3.2 63.3 ± 3.5 0.11
1Values are means± SEs unless otherwise indicated. MET, metabolic equivalent task;
NHS2, Nurses’ Health Study II; OC, oral contraceptive.
2P values correspond to t tests for continuous variables and chi-square tests for
categorical variables.
3Values are means ± SDs.
4Among ever smokers only.
5Among ever OC users only.
with lower 25(OH)D concentrations and earlier age at menopause.
Accordingly, we conducted analyses excluding individuals diagnosed
with these conditions at any point during follow-up. Similarly, we
conducted analyses limited to women with luteal phase samples in order
to address the potential impact of variation in biomarker measures
due to menstrual cycle variability. We also conducted analyses limited
to never smokers to evaluate potential residual confounding due to
misclassification of smoking amount among smokers. All of the analyses
were conducted with the use of SAS version 9.4 software (SAS Institute,
Inc.). We used 2-sided statistical tests performed at the 0.05 significance
level for all analyses.
Results
Characteristics of cases and controls at the time of blood
collection are presented in Table 1. At the time of blood
collection, cases were more likely to identify as nonwhite and
to smoke and reported lower intakes of alcohol, supplemental
calcium, and total vitamin D and calcium than controls.
In unadjusted analyses and analyses adjusting for important
covariates, total 25(OH)D concentrations were not associated
with risk (Table 2). For example, the OR comparing the first and
fourth quartile of total 25(OH)Dwas 1.04 (95%CI: 0.60, 1.81)
in our multivariable (MV) 1 model. Results for free 25(OH)D
were suggestive of a lower risk at the highest concentrations,
but CIs were wide and results were not significant (quartile 4
compared with quartile 1—OR: 0.70; 95% CI: 0.41, 1.20).
High VDBP was associated with increased risk, and results
were stronger after adjustment for variables in MV1, with
some evidence of a threshold of higher risk for quartiles 3
and 4 compared with quartile 1 (quartile 3 compared with
quartile 1—OR: 1.80; 95% CI: 1.10, 2.95; quartile 4 compared
with quartile 1—OR: 1.80; 95% CI: 1.09, 2.98). Results
comparing women with total 25(OH)D concentrations
≥75 nmol/L compared with those with concentrations
<50 nmol/L were null (MV2—OR: 1.19; 95% CI: 0.57,
2.46) (Supplemental Table 1). For each exposure, results from
restricted cubic spline models indicated no associations with
early menopause—either linear or nonlinear (P for all exposures
>0.10; complete results not shown).
We did not find that adjusted geometric means of AMH
concentrations varied according to quartile of total (P = 0.55)
or free 25(OH)D (P = 0.32) concentrations (Table 3). AMH
geometric mean concentrations varied significantly across
VDBP quartiles, with the lowest concentrations in quartiles 3
and 4 (P = 0.04).
Findings of the primary analyses were largely unchanged
in models evaluating effect modification and in sensitivity
analyses. Estimates from analyses of total 25(OH)D stratified
by median age at blood draw (<40 or ≥40 y) were consistent
with findings from main analyses (data not shown). Estimates
for total 25(OH)D stratified by BMI (underweight/normal and
overweight/obese) were unstable due to small numbers (data not
shown). Season (summer/fall compared with winter/spring) did
not modify associations for total 25(OH)D or free 25(OH)D
(P-interaction = 0.31 and 0.85, respectively). Estimates were
also similar after restricting analyses to nonsmokers (n = 222
cases and 216 controls), women who provided timed blood
samples (n = 254 cases and 254 controls), and women without
diagnoses of autoimmune conditions (n = 321 cases and 319
controls). We also conducted models using only “super-normal
controls,”defined as women who experienced menopause at the
population mean age of 51 y (n = 328 cases and 63 controls).
Estimates from these models were not materially different than
those of our main analyses. For example, the MV1 OR for each
1-SD increase in total 25(OH)D was 1.29 (95% CI: 0.87, 1.91)
and for free 25(OH)D was 1.00 (95% CI: 0.68, 1.46).
Discussion
In this prospective study, we did not find vitamin D metabolite
concentrations to be consistently or strongly associated with
the risk of early menopause, or with concentrations of plasma
AMH, a marker of ovarian aging. Conversely, high compared
with low VDBP concentrations were associated with increased
risk of early menopause and lower AMH concentrations.
To our knowledge, this is the first study to investigate
the association of total and free 25(OH)D and VDBP con-
centrations and risk of early menopause. A recent study in
NHS2 participants by our research group observed a significant
17% lower risk of early menopause among women who
consumed the highest vitamin D from food sources (quintile 5
median = 528 IU/d), as compared with those who consumed
the least (quintile 1 median = 148 IU/d) (11). In contrast, we
observed that total vitamin D intake was not associated with
risk, whereas supplemental vitamin D intake (≥600 compared
with 0 IU/d) was associated with increased risk. The lack of
strong and consistent associations of 25(OH)D with risk in
1448 Purdue-Smithe et al.
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TABLE 2 Unadjusted and multivariable ORs (95% CIs) for early menopause according to quartile of total and free 25(OH)D and
VDBP concentrations: NHS2 (1996–2011)1
Quartile
Biomarker n/Q1 = 169 n/Q2 = 175 n/Q3 = 153 n/Q4 = 159 P 2 Continuous3
Total 25(OH)D
Median, nmol/L 44.2 59.8 71.7 90.4
Cases:controls, n:n 86:83 92:83 71:82 79:80
Unadjusted OR4 (95% CI) 1 1.07 (0.70, 1.64) 0.81 (0.51, 1.29) 0.91 (0.56, 1.48) 0.69 1.02 (0.83, 1.25)
MV1 1 1.21 (0.75, 1.93) 0.93 (0.56, 1.54) 1.04 (0.60, 1.81) 0.75 1.12 (0.89, 1.42)
MV2 1 1.18 (0.73, 1.89) 0.88 (0.53, 1.46) 0.96 (0.55, 1.69) 0.70 1.09 (0.85, 1.38)
Free 25(OH)D
Median, pmol/L 13.9 18.7 24.2 32.4
Cases:controls, n:n 94:83 91:85 81:80 62:80
Unadjusted OR4 (95% CI) 1 0.92 (0.60, 1.40) 0.87 (0.56, 1.34) 0.65 (0.41, 1.05) 0.32 0.82 (0.67, 0.99)
MV1 1 1.02 (0.64, 1.62) 0.98 (0.61, 1.57) 0.70 (0.41, 1.20) 0.44 0.85 (0.68, 1.05)
VDBP
Median, µg/mL 145.4 203.0 248.2 305.3
Cases:controls, n:n 56:81 87:81 86:83 99:83
Unadjusted OR4 (95% CI) 1 1.54 (0.99, 2.41) 1.49 (0.96, 2.34) 1.75 (1.11, 2.77) 0.10 1.16 (0.99, 1.36)
MV1 1 1.54 (0.94, 2.51) 1.80 (1.10, 2.95) 1.80 (1.09, 2.98) 0.07 1.17 (0.99, 1.39)
MV2 1 1.50 (0.92, 2.46) 1.77 (1.08, 2.90) 1.77 (1.06, 2.94) 0.09 1.16 (0.98, 1.38)
1MV1 adjusted for matching factors plus physical activity (<9, 9 to <42, or ≥42 MET-h/wk), duration of breastfeeding at blood draw (0, >0–6, >6–18, or >18 mo), smoking
status at blood draw (nonsmoker or current smoker), BMI (kg/m2; <25 or ≥25), and intakes of alcohol (0, 0.1–9.9, 10.0–29.9, or ≥30.0 g/d) and percentage of vegetable protein
(continuous) at blood draw. MV2 adjusted for covariates in MV1 plus mutual adjustment for total 25(OH)D and VDBP. MET, metabolic equivalent task; MV, multivariable; NHS2,
Nurses’ Health Study II; Q, quartile; VDBP, vitamin D–binding protein; 25(OH)D, 25-hydroxyvitamin D.
2P values correspond to likelihood ratio tests comparing models with and without indicator variables for exposures.
3ORs correspond to a 1-SD increase in exposure.
4Model adjusted for matching factors only [i.e., age at blood collection (within 4 mo), time of day of blood collection, month of collection (within 3 mo), sample type (luteal phase
or untimed), and fasting status].
the present analysis suggests that other dietary components
or lifestyle factors correlated with vitamin D in foods may
be associated with early menopause, rather than vitamin D
itself. In our previous study, we noted a stronger association
for dairy sources of vitamin D compared with nondairy dietary
vitamin D. Other constituents of dairy, such as lactose, calcium,
or progesterone, which are highly correlated with vitamin D
in dairy, may have influenced the observed inverse association
for dietary vitamin D. The potential importance of dairy foods
generally, rather than vitamin D specifically, is also supported
by findings of Carwile et al. (28), who observed that low-fat
dairy intake was associated with later age at menopause, among
women aged <51 y. To answer this question, future studies of
dairy foods and dairy constituents and risk of early menopause
are warranted.
Vitamin D has been hypothesized to be related to
ovarian aging and menopause timing primarily through
effects on AMH and follicular development. Our null
findings for 25(OH)D and AMH are consistent with those
of 3 cross-sectional studies (14, 15, 29). Pearce et al.
(14) observed no association of 25(OH)D and AMH
among 340 infertility treatment-seeking women <40 y
of age living in South Australia. Similarly, Drakopoulos et al.
(15) also observed no association of 25(OH)D concentrations
and AMH among an infertile population of 283 Belgian women
<42 y of age, and Kim et al. (29) observed no association of
25(OH)D and AMH concentrations in 291 Korean women
35–49 y of age.
In contrast, 2 other studies reported significant associations
between 25(OH)D and AMH. In a clinical trial in 33
premenopausal women living inNewZealand,Dennis et al. (13)
observed seasonal variation of AMH concentrations mirroring
that of 25(OH)D in both direction and magnitude, as well
as a stabilizing effect of cholecalciferol supplementation on
the seasonality of AMH concentrations. This is in contrast
to placebo and ergocalciferol supplementation groups, who
experienced a significant decline in AMH concentrations from
summer to winter months. In another small trial, Naderi et al.
(30) reported a significant increase in both 25(OH)D and AMH
concentrations after 3 mo of vitamin D supplementation among
30 infertile Iranian women with vitamin D insufficiency or defi-
ciency. Likewise, in a cross-sectional study in US women,Merhi
et al. (12) observed a significant 1.1% higher log-transformed
AMH for each 1-ng/mL higher 25(OH)D concentration among
388 women aged ≥40 y, but no association among younger
women.
The inconsistency in findings between studies of 25(OH)D
and AMHmay potentially be explained by 2 important factors.
First, it is possible that 25(OH)D may only be associated
with changes in AMH concentrations among vitamin D–
deficient women. Both the Kim et al. trial (29) and the Merhi
et al. (12) study were conducted in predominantly vitamin D–
deficient women. The Dennis et al. trial (13) did not provide
baseline 25(OH)D concentrations of participants, but given
the high latitude of residence of the study population, these
women may have been vitamin D deficient before receiving
the supplement or placebo, and thus supplementation may
have been beneficial in preventing a seasonal decline in
25(OH)D and AMH concentrations. If a 25(OH)D–AMH
association is only observable at the low end of the vitamin
D spectrum, then one would expect to see an association only
in populations with a high prevalence of vitamin D deficiency,
which the NHS2 is not. Given the small numbers of women
with 25(OH)D concentrations <35 nmol/L (n = 28) in the
NHS2, we were unable to address this possibility in our
analyses.
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TABLE 3 Unadjusted and adjusted AMH geometric means
(95% CIs) according to quartile of total and free 25(OH)D and
VDBP: NHS2 (1996–2011)1
AMH geometric mean (95%
CI), ng/mL
n Range Unadjusted Adjusted2
Total 25(OH)D, nmol/L
Q1 169 22.9–52.1 0.4 (0.3, 0.6) 0.5 (0.4, 5.8)
Q2 175 52.2–65.8 0.4 (0.3, 0.5) 0.4 (0.3, 4.6)
Q3 153 65.9–78.8 0.4 (0.3, 0.5) 0.4 (0.3, 5.4)
Q4 159 78.8–159.0 0.4 (0.3, 0.5) 0.4 (0.3, 4.8)
P 3 0.65 0.55
Free 25(OH)D, pmol/L
Q1 177 6.8–16.2 0.4 (0.3, 0.5) 0.4 (0.3, 0.5)
Q2 176 16.3–21.4 0.4 (0.3, 0.5) 0.4 (0.3, 0.5)
Q3 161 21.6–27.5 0.4 (0.3, 0.5) 0.4 (0.3, 0.5)
Q4 142 27.5–88.9 0.5 (0.4, 0.6) 0.5 (0.4, 0.6)
P 3 0.35 0.32
VDBP, µg/mL
Q1 137 48.7–177.7 0.5 (0.4, 0.7) 0.5 (0.4, 0.7)
Q2 168 178.2–224.3 0.4 (0.3, 0.5) 0.4 (0.3, 0.6)
Q3 169 224.8–272.0 0.4 (0.3, 0.5) 0.4 (0.3, 0.5)
Q4 182 272.6–425.8 0.3 (0.3, 0.4) 0.3 (0.3, 0.4)
P 3 0.07 0.04
1AMH, anti-Müllerian hormone;MET,metabolic equivalent task; NHS2, Nurses’ Health
Study II; Q, quartile; VDBP, vitamin D–binding protein; 25(OH)D, 25-hydroxyvitamin D.
2Multivariable model 1 adjusted for matching factors plus physical activity (<9, 9
to <42, or ≥42 MET-h/wk), duration of breastfeeding at blood draw (0, >0–6, >6–
18, or >18 mo), smoking status at blood draw (nonsmoker vs. current smoker),
BMI (kg/m2; <25 or ≥25), and intakes of alcohol (0, 0.1–9.9, 10.0–29.9, or ≥30.0 g/d)
and percentage of vegetable protein (continuous) at blood draw.
3P values corresponds to type III P values.
It is also possible that the 25(OH)D–AMH relation may
vary across racial groups due to differences in VDBP, because
VDBP concentrations and binding affinity are determined
almost entirely by genetic polymorphisms specific to race
and ethnicity (31). The binding affinity and concentration of
VDBP are directly related to the bioavailability of 25(OH)D
within the body, and thus may be biologically relevant to
the mechanisms involved in ovarian aging. In our study, we
observed a threshold of higher risk for early menopause among
individuals in quartiles 2 through 4 of VDBP compared with
quartile 1, and a nonlinear relation of VDBP with AMH
concentrations, suggesting that VDBP concentrations and/or
their genetic determinants may be associated with risk. The
NHS2, as well as the study populations of Pearce et al.
(14) and Drakopoulos et al. (15) were almost entirely white,
whereas that of Merhi et al. (12) was predominantly black
and Hispanic. If 25(OH)D is only associated with AMH in
specific racial/ethnic groups, demographic differences in study
populations, and thus the underlying population heterogeneity
of VDBP polymorphisms, may provide some explanation for
inconsistent findings.
Our ability to evaluate associations of early menopause and
AMH with free 25(OH)D and VDBP in nonwhite individuals
was limited for 2 reasons. First, given the racial homogeneity
of the NHS2, we used a monoclonal rather than a polyclonal
assay tomeasure VDBP,which has been shown to underestimate
free 25(OH)D concentrations in nonwhite individuals (32).
Second, the NHS2 is composed mostly of white women,
and thus numbers of nonwhite individuals were too small to
conduct race-stratified analyses. In light of evidence that the
25(OH)D–AMH relation may vary by race potentially due to
VDBP differences, additional evaluation of 25(OH)D, VDBP,
and AMH in large, diverse populations is necessary.
It is important to note additional limitations of our study.
First, we relied upon single measurements of 25(OH)D, VDBP,
and AMH. Because 25(OH)D concentrations are influenced
heavily by recent sun exposure and dietary intake, it is
possible that within-person variability in 25(OH)D concen-
trations may have contributed measurement error, resulting
in nondifferential misclassification. However, in the NHS, a
similar population of female health professionals, the intraclass
correlation coefficient for plasma 25(OH)D measured 2–3 y
apart was 0.72 (P < 0.001) (33), and for measurements 10 y
apart was 0.51 (95% CI: 0.42, 0.60) (34). In a comparable
population, the intraclass correlation coefficient for VDBP
measured over 1–3 y was 0.96 (P < 0.001) (35), indicating that
these biomarkers are relatively stable over time. Furthermore,
although some researchers have raised questions about potential
misclassification of vitamin D deficiency status when 25(OH)D
concentrations are measured by immunoassay, this technique is
widely used and well validated for studies comparing disease
risk across relative 25(OH)D concentrations, such as our
study (36). These factors help minimize the possibility that
measurement error in biomarker data would explain our null
findings for total and free 25(OH)D.
Second, we relied upon self-report of age at menopause,
defined as the age at which periods were absent for 12 mo, to
ascertain cases and controls. Because women may experience
amenorrhea and then have periods return again during
perimenopause, some degree of measurement error in self-
reported age at menopause is to be expected. Such measurement
error would result in misclassification of early menopause cases
and controls and produce a bias toward the null. However,
among 6591 women in the comparable NHS population,
82% of women reported the same age at menopause over
multiple questionnaire cycles, suggesting high reproducibility
(37). Furthermore, we restricted the control group to
women with age at menopause >48 y to reduce potential
misclassification of the outcome. As such, misclassification of
cases and controls would be an unlikely explanation for our
findings.
Third, it is possible that residual confounding may have
influenced our estimates. However, we were able to control
for previously identified risk factors for early menopause such
as smoking, vegetable protein intake, and BMI. None of the
covariates included in multivariable models produced a change
>10% in exposure estimates and unadjusted estimates were
similar to fully adjusted estimates, suggesting that substantial
bias due to residual confounding is unlikely.
There are also several notable strengths of our study, which
extend on design limitations and findings of previous research
in this area. First, this was the first study, to our knowledge,
to evaluate the association of 25(OH)D and early menopause.
Not only did we assess total 25(OH)D,we also evaluated VDBP
and free 25(OH)D, which represents the biologically active
vitaminD fraction and has beenmore strongly related to the risk
of some health outcomes than total 25(OH)D alone. Second,
the size of our study population was larger than previous
studies evaluating 25(OH)D and AMH,which provided greater
statistical power and also allowed us to consider a wide variety
of potential confounders. Finally, because most previous studies
of 25(OH)D and AMH have been conducted in women seeking
treatment for infertility, we anticipate that our findings are more
widely generalizable to healthy premenopausal women. In the
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context of our findings and those of the aforementioned studies,
it appears that 25(OH)D is unlikely to be related to AMH or
early menopause, at least among white premenopausal women
without vitamin D deficiency.
In conclusion, the findings of our study do not suggest that
25(OH)D concentrations are importantly related to the risk
of early menopause. Modest positive associations of VDBP
concentrations with the risk of early menopause and AMH
concentrations warrant further evaluation in large, ethnically
diverse populations.
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